Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Spyre Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CG Oncology, Inc. (CGON) and Spyre Therapeutics (SYR...

Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON) and Spyre Therapeutics (SYRE)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Spyre Therapeutics yesterday and set a price target of $103.00. According to TipRank...

LifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mereo Biopharma Group Plc (MREO), DocGo (DCGO) and S...

Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), DocGo (DCGO) and Spyre Therapeutics (SYRE)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Spyre Therapeutics yesterday and set a price target of $103.00. Slutsky covers the H...

Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Spyre Therapeutics, with a price target of $95.00. According to ...

Jefferies Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and uniQure (QURE) with bu...

Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), uniQure (QURE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spyre Therapeutics (SYRE), AxoGen (AXGN) and Wave Li...

Market Cap	$1.65B	P/E Ratio	N/A
52W High	$76.00	52W Low	$13.93
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	56.9%	52W Position	96.2%
Overall Score	49	Value Score	60
Quality Score	21	Technical Score	66

EPS Current Est	$-2.79	EPS Next Est	$-3.12
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SYRE	$73.65	-0.54%	478.43K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SYRE	$73.65	-0.5%	478.43K
3
4
5
6

SYRE

SYRE

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Spyre Therapeutics Inc. Data in Excel

Get Spyre Therapeutics Inc. Data in Excel